This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.
Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.